Updates are available Correction dated 2024-08-28
Click to view Correction: https://doi.org/10.1038/s41698-024-00676-w
-
Authors
Thawani, Rajat http://orcid.org/0000-0002-5378-9434
Repetto, Matteo
Keddy, Clare
Nicholson, Katelyn
Jones, Kristen
Nusser, Kevin
Beach, Catherine Z. http://orcid.org/0000-0003-0750-3658
Harada, Guilherme
Drilon, Alexander http://orcid.org/0000-0001-6806-9061
Davare, Monika A.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P30CA008748, R01CA273224, P30CA008748, P30CA008748, R01CA233495)
U.S. Department of Health & Human Services | National Institutes of Health
Oregon Early Career Investigator Award
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 12 January 2024
Accepted: 22 July 2024
First Online: 8 August 2024
Change Date: 28 August 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41698-024-00676-w
Competing interests
: Dr. Drilon reports Honoraria/Advisory Boards: 14ner/Elevation Oncology, Amgen, Abbvie, ArcherDX, AstraZeneca, Beigene, BergenBio, Blueprint Medicines, Chugai Pharmaceutical, EcoR1, EMD Serono, Entos, Exelixis, Helsinn, Hengrui Therapeutics, Ignyta/Genentech/Roche, Janssen, Loxo/Bayer/Lilly, Merus, Monopteros, MonteRosa, Novartis, Nuvalent, Pfizer, Prelude, Repare RX, Takeda/Ariad/Millenium, Treeline Bio, TP Therapeutics, Tyra Biosciences, Verastem; Associated Research to Institution: Foundation Medicine, Teva, Taiho, GlaxSmithKlein; Equity: mBrace, Treeline; Copyright: Selpercatinib-Osimertinib (pending); Royalties: Wolters Kluwer, UpToDate, Food/Beverage: Boehringer Ingelheim, Merck, Puma: CME Honoraria: Answers in CME, Applied Pharmaceutical Science, Inc., AXIS, Clinical Care Options, EPG Health, Harborside Nexus, I3 Health, Imedex, Liberum, Medendi, Medscape, Med Learning, MJH Life Sciences, MORE Health, Ology, OncLive, Paradigm, Peerview Institute, PeerVoice, Physicians Education Resources, Remedica Ltd., Research to Practice, RV More, Targeted Oncology, TouchIME, WebMD. Dr. Davare reports consulting for Nuvalent. The remaining authors declare no competing interests.
